Evidence map›Paper›PMID 33723575›Full record

ReviewCardiovascular research2021

New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation.

Martin Aguilar, Robert A Rose, Abhijit Takawale, Stanley Nattel, Svetlana Reilly

Open access · hybridAbstract readReview
In one paragraph

Review in Cardiovascular research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Metabolic and Inflammatory Mechanisms Driving Atrial Fibrillation.Annual review of pharmacology and toxicology · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 4 countries.

Martin AguilarDepartment of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Montréal, QC, Canada.ORCID 0000-0002-1622-9876
Robert A RoseDepartment of Cardiac Sciences, Department of Physiology and Pharmacology, Libin Cardiovascular Institute, Cumming School of Medicine, Health Research Innovation Center, University of Calgary, AB, Canada.ORCID 0000-0001-9880-3482
Abhijit TakawaleDepartment of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Montréal, QC, Canada.
Stanley NattelDepartment of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.
Svetlana ReillyDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital, Oxford, UK.ORCID 0000-0003-1231-1239
Montreal Heart Institute · CAJohn Radcliffe Hospital · GBUniversity of Calgary · CA

Funding

British Heart Foundation FS/16/5/32054CIHR 148401CIHR MOP142486CIHR PJT 166105
6 · The paper itself

Abstract

Hormones are potent endo-, para-, and autocrine endogenous regulators of the function of multiple organs, including the heart. Endocrine dysfunction promotes a number of cardiovascular diseases, including atrial fibrillation (AF). While the heart is a target for endocrine regulation, it is also an active endocrine organ itself, secreting a number of important bioactive hormones that convey significant endocrine effects, but also through para-/autocrine actions, actively participate in cardiac self-regulation. The hormones regulating heart-function work in concert to support myocardial performance. AF is a serious clinical problem associated with increased morbidity and mortality, mainly due to stroke and heart failure. Current therapies for AF remain inadequate. AF is characterized by altered atrial function and structure, including electrical and profibrotic remodelling in the atria and ventricles, which facilitates AF progression and hampers its treatment. Although features of this remodelling are well-established and its mechanisms are partly understood, important pathways pertinent to AF arrhythmogenesis are still unidentified. The discovery of these missing pathways has the potential to lead to therapeutic breakthroughs. Endocrine dysfunction is well-recognized to lead to AF. In this review, we discuss endocrine and cardiocrine signalling systems that directly, or as a consequence of an underlying cardiac pathology, contribute to AF pathogenesis. More specifically, we consider the roles of products from the hypothalamic-pituitary axis, the adrenal glands, adipose tissue, the renin-angiotensin system, atrial cardiomyocytes, and the thyroid gland in controlling atrial electrical and structural properties. The influence of endocrine/paracrine dysfunction on AF risk and mechanisms is evaluated and discussed. We focus on the most recent findings and reflect on the potential of translating them into clinical application.

Indexed as

Renin-Angiotensin SystemAdrenal GlandsAnimalsAnti-Arrhythmia AgentsAtrial FibrillationCalcitoninDiabetes MellitusEndocrine SystemHeart AtriaHumansHypothalamo-Hypophyseal SystemNatriuretic PeptidesObesityRisk FactorsSignal TransductionThyroid DiseasesAnti-Arrhythmia AgentsCalcitoninNatriuretic PeptidesArrhythmiaAtrial fibrillationEndocrine systemHeart

Identifiers

PMID33723575
PMCPMC8208746
OpenAlexW3137406268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.